Pravastatin

Pravastatin has been studied in 70 papers since 1993: 15 trials and 19 observational studies in people, 11 in animals, 7 in cells, 15 reviews; 26 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.

InterventionStatinsApproved 1991

70 papers study it22 more mention it56 findingsUpdated

PubChemChEBIMeSH

5 new papers in 30 daysSee all 90 papers on pravastatin

At a glance

Human trials report lower mortality with pravastatin, replicated by independent labs, but others show no clear mortality benefit; a trial reports shorter survival in adults 65 and older without cardiovascular disease. Independent human studies report cholesterol reductions but disagree on coenzyme Q10. Some authors have company affiliations, papers declare company ties, and Bristol Myers Squibb sponsors some registered trials.

56 findings in 27 papers from 1993 to 2026, 4 of them since July 2026

Independent labs found the same change in cells and people. 27 independent labs in 14 countries; 95 trials, 6 about aging, 55 with no results posted.

“the risk ratio was 0.79 (0.68, 0.91) for death”
Estimating the effect of pravastatin vs usual care under full adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering TrialAmerican journal of epidemiology2026doi:10.1093/aje/kwag049

7 of its findings point the other way.

Cells and humans: replicated by independent labs. Worms or flies and mice: a single group.
  • 27 independent labs in 14 countries
  • 7 findings against
  • 95 trials, 6 about aging, 55 with no results posted
  • Funders: Bristol Myers Squibb and others
  • 8 of 57 findings with company ties
  • 7 of 95 trials sponsored by its developers
  • Human trial15
  • Humans19
  • Animals10
  • Cells7
  • In silico2

11 studies gave pravastatin to people and measured what changed.

What changedDesignPeopleSource

down: Protects against mortalityRR 0.79 (0.68, 0.91), risk difference -3.0% (-4.9%, -1.3%)

Randomized trial5 year9,741 people≥55 years oldMidlife adults; Older adults; moderately hypercholesterolemic, hypertensive, under full adherenceAmerican journal of epidemiology, Mar 6, 2026

down: Lowers the risk of mortality

Randomized trial3.2 years5,749 people70–82 yearsOlder population with a history or increased risk of CVDJHEP reports : innovation in hepatology, Feb 7, 2025

down: Lowers the risk of strokeHR .93; 95% CI .22–3.91

no change: Has no effect on cardiovascular disease

Randomized trialmean follow‐up of 3.2 years (range: 2.8–4.0)5,804 peopleaged 70–82Elderly individuals at risk of vascular diseaseEuropean journal of clinical investigation, Dec 5, 2024

down: Decreases bone attenuation-2.6% vs 0% median change (atorvastatin)

Randomized trial12 months420 peopleWomenPostmenopausal women; Patient cohortsAtherosclerosis, Dec 12, 2023

down: Decreases cardiovascular events-78 events per 10 000 person-years (95% CI, -144 to -12)

Randomized trial2,891 people70-82 yearsOlder adults; prescribing pravastatin to all participantsEuropean journal of preventive cardiology, Dec 12, 2023

What did lifespan studies of pravastatin find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in B. manjavacas. Average lifespan is the mean or the median, as each paper reports it.

What did studies of pravastatin find?

40

Studies of pravastatin measured 40 outcomes; the most studied are coenzyme Q10 (4 studies), mortality (2) and cell proliferation (2).

Coenzyme Q10

no changein humans2downin humans2−40% reduction

4 studies
  1. Pravastatin showed no clear effect on coenzyme Q10 in humans (0.61 +/- 0.14 vs 0.62 +/- 0.2 microg/mL, P >.05).

    “There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A”

    Human trial20 mg4 weeks

    The effect of pravastatin and atorvastatin on coenzyme Q10

    American heart journal

  2. Pravastatin decreases coenzyme Q10 in humans (hypercholesterolemia) (from 1.27 +/- 0.34 to 1.02 +/- 0.31 mmol/l, P < 0.01).

    “A dose-related significant decline of the total serum level of coenzyme Q10 was found in the pravastatin group from 1.27 +/- 0.34 at baseline to 1.02 +/- 0.31 mmol/l”

    Human trialhypercholesterolemia10-40 mg/day18 weeks

    Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors

    Molecular aspects of medicine

  3. Pravastatin decreases coenzyme Q10 in humans (hypercholesterolemia; compared with placebo) (About 40% reduction).

    “The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin.”

    Human trialhypercholesterolemia; compared with placeboplasma20 mg/day3 monthsn = 30

    Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

    Journal of clinical pharmacology

  4. Pravastatin was not clearly linked with coenzyme Q10 in humans (coronary artery disease).

    “it did not improve either the ubiquinone level or the LDL/ubiquinone ratio.”

    Humanscoronary artery diseaseplasma

    Coenzyme Q10 and coronary artery disease

    The Clinical investigator

More on Coenzyme Q10

Mortality

downin humans1no changein humans1RR 0.79

2 studies
  1. Pravastatin protects against mortality in humans (moderately hypercholesterolemic, hypertensive, under full adherence) (RR 0.79 (0.68, 0.91), risk difference -3.0% (-4.9%, -1.3%)).

    “the risk ratio was 0.79 (0.68, 0.91) for death”

    Human trialmoderately hypercholesterolemic, hypertensive, under full adherence40 mg/day5 yearn = 9,741

    Trial reanalysis links pravastatin adherence to fewer deaths

    American journal of epidemiology

  2. Pravastatin showed no clear effect on mortality in humans (HR 1.18 (95% CI 0.97-1.42)).

    “The hazard ratios for all-cause mortality in the pravastatin group vs the UC group were 1.18 (95% CI, 0.97-1.42; P = .09) for all adults 65 years and older”

    Human trial40 mg/dn = 2,867

    Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial

    JAMA internal medicine

Cell proliferation

downin cells1downin human cells1

2 studies
  1. Pravastatin decreases cell proliferation in cystic cholangiocytes in culture.

    “It also normalized mitochondrial hyperactivity and reduced the proliferation of cystic cholangiocytes in culture”

    Cellsin cystic cholangiocytes in culture

    Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes

    Hepatology (Baltimore, Md.)

  2. Pravastatin inhibits cell proliferation in human cells (senescent cells).

    “selectively inhibits the proliferation of senescent cells”

    Cellssenescent cellslung fibroblast

    Selective Growth Suppressive Effect of Pravastatin on Senescent Human Lung Fibroblasts

    Die Pharmazie

Low-density lipoprotein cholesterol

downin humans2

2 studies
  1. Pravastatin decreases low-density lipoprotein cholesterol in humans (109.1 vs 128.8 mg/dL at year 6).

    “by year 6, the mean (SD) low-density lipoprotein cholesterol levels were 109.1 (35.4) mg/dL in the pravastatin group and 128.8 (27.5) mg/dL in the UC group.”

    Human trial40 mg/dyear 6

    Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial

    JAMA internal medicine

  2. Pravastatin decreases low-density lipoprotein cholesterol in humans (97 +/- 21 vs 66 +/- 19 mg/dL, P <.01).

    “There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A”

    Human trial20 mg4 weeks

    The effect of pravastatin and atorvastatin on coenzyme Q10

    American heart journal

More on Low-density lipoprotein cholesterol

Total cholesterol

downin humans2−40% reduction

2 studies
  1. Pravastatin decreases total cholesterol in humans (hypercholesterolemia; compared with placebo) (About 40% reduction).

    “The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin.”

    Human trialhypercholesterolemia; compared with placeboplasma20 mg/day3 monthsn = 30

    Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

    Journal of clinical pharmacology

  2. Pravastatin is linked with lower total cholesterol in humans (coronary artery disease).

    “The present study revealed that HMG CoA reductase inhibitor decreased plasma cholesterol level”

    Humanscoronary artery diseaseplasma

    Coenzyme Q10 and coronary artery disease

    The Clinical investigator

More on Total cholesterol

TLR4 signaling

downin rats1

1 study
  1. Pravastatin inhibits TLR4 signaling in rats (excessive hypercholesterolemia in pregnancy).

    “In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4”

    Animalsexcessive hypercholesterolemia in pregnancyuterine artery5 mg/kg/dayGD10-20females

    Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

    Clinical science (London, England : 1979)

Carotid artery endothelial function

no changein rats1

1 study
  1. Pravastatin showed no clear effect on carotid artery endothelial function in rats (excessive hypercholesterolemia in pregnancy).

    “In carotid arteries, endothelial function was unchanged;”

    Animalsexcessive hypercholesterolemia in pregnancycarotid artery5 mg/kg/dayGD10-20females

    Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

    Clinical science (London, England : 1979)

Uterine artery endothelial function

upin rats1

1 study
  1. Pravastatin improves uterine artery endothelial function in rats (excessive hypercholesterolemia in pregnancy).

    “In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4, while also increasing nitric oxide-mediated vasodilation.”

    Animalsexcessive hypercholesterolemia in pregnancyuterine artery5 mg/kg/dayGD10-20females

    Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

    Clinical science (London, England : 1979)

Colony formation

downin human cells1

1 study
  1. Pravastatin decreases colony formation in human cells (primary human DNMT3A R882-mutant PBMCs relative to wild-type).

    “In vitro, pravastatin selectively suppressed colony formation of primary human DNMT3A R882-mutant relative to wild-type cells (P=0.031).”

    Cellsprimary human DNMT3A R882-mutant PBMCs relative to wild-typeperipheral blood mononuclear cell

    Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis

    medRxiv : the preprint server for health sciencesPreprint

CAV1

upin human cells1

1 study
  1. Pravastatin increases CAV1 in uterine radial arteries from preeclamptic pregnancies.

    “Myoendothelial gap junction and endothelial caveolae density, and caveolin-1 and endothelial-NOS expression were decreased in arteries from PE relative to NT pregnancies and increased following pravastatin incubation.”

    Cellsin uterine radial arteries from preeclamptic pregnanciesuterine radial artery2 mM6 h

    Pravastatin Corrects Endothelial Dysfunction in Ex Vivo Uterine Radial Arteries in Preeclampsia

    Acta physiologica (Oxford, England)

More on CAV1

Cardiovascular disease

no changein humans1

1 study
  1. Pravastatin showed no clear effect on cardiovascular disease in elderly subjects with obesity and liver fibrosis.

    “Pravastatin did not affect other cardiovascular endpoints in elderly subjects with obesity and liver fibrosis.”

    Human trialin elderly subjects with obesity and liver fibrosismean follow‐up of 3.2 years (range: 2.8–4.0)

    Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment

    European journal of clinical investigation

More on Cardiovascular disease

Bone attenuation

downin humans1

1 study
  1. Pravastatin decreases bone attenuation in humans (compared with atorvastatin 80 mg/day) (-2.6% vs 0% median change (atorvastatin)).

    “At follow-up, the median bone attenuation loss was significantly greater with PRV than with ATV [-2.6 (-27 to 11)% vs 0 (-11 to 25)%; p < 0.001].”

    Human trialcompared with atorvastatin 80 mg/daythoracic vertebrae40 mg/day12 monthsfemalesn = 420

    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial

    Atherosclerosis

More on Bone attenuation

Cardiovascular events

downin humans1

1 study
  1. Pravastatin decreases cardiovascular events in humans (prescribing pravastatin to all participants) (-78 events per 10 000 person-years (95% CI, -144 to -12)).

    “-78 events (95% CI, -144 to -12) when prescribing pravastatin to all participants”

    Human trialprescribing pravastatin to all participantsn = 2,891

    The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial

    European journal of preventive cardiology

Coronary artery disease

no changein humans1

1 study
  1. Pravastatin showed no clear effect on coronary artery disease in humans (primary prevention in adults 65+ free of cardiovascular disease) (+18.7 days CHD-free survival, 95% CI -10.4 to 47.8, p=.21).

    “18.7 more days free of CHD over 6 years than those receiving usual care (RMST 2,069.4 days), but this difference was not statistically significant (difference 18.7 days, 95% CI=-10.4-47.8 days, p=.21)”

    Human trialprimary prevention in adults 65+ free of cardiovascular disease40 mg/d6 yearsn = 2,867

    Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis

    Journal of the American Geriatrics Society

More on Coronary artery disease

Survival

downin humans1

1 study
  1. Pravastatin decreases survival in humans (primary prevention in adults 65+ free of cardiovascular disease) (-33.7 days, 95% CI -67.0 to -0.5, p=.047).

    “individuals treated with pravastatin lived (RMST 2,008.1 days), on average, 33.7 fewer days than those receiving usual care (RMST 2,041.8 days) (difference -33.7 days, 95% confidence interval (CI)=-67.0 to -0.5 days, p=.047)”

    Human trialprimary prevention in adults 65+ free of cardiovascular disease40 mg/d6 yearsn = 2,867

    Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis

    Journal of the American Geriatrics Society

All 40

What is pravastatin linked with?

7

Studies link pravastatin with 7 measures, among them mortality, stroke and cardiovascular events.

Mortality

downin humans1

1 study
  1. Pravastatin lowers the risk of mortality in humans (depending on FIB-4 classification).

    “The interaction term between FIB-4 class and statin treatment was significant (p = 0.049), indicating that the effect of treatment depended on FIB-4 classification (or vice versa).”

    Human trialdepending on FIB-4 classification3.2 years

    Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial

    JHEP reports : innovation in hepatology

  2. Pravastatin lowers the risk of mortality in humans (high FIB-4 classification) (interaction p = 0.049).

    “In the pravastatin group, the HR for all-cause mortality was not associated with FIB-4 classification: high-class HR = 1.01 (95% CI, 0.69-1.49).”

    Human trialhigh FIB-4 classification

    Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial

    JHEP reports : innovation in hepatology

Stroke

downin humans1

1 study
  1. Pravastatin lowers the risk of stroke in elderly subjects with obesity and liver fibrosis (HR .93; 95% CI .22–3.91).

    “In the group on pravastatin, no increased risk was present for that group (HR.93; 95% CI.22–3.91).”

    Human trialin elderly subjects with obesity and liver fibrosismean follow‐up of 3.2 years (range: 2.8–4.0)

    Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment

    European journal of clinical investigation

  2. Pravastatin lowers the risk of stroke in humans (high FIB-4 and obesity).

    “Elderly individuals with obesity and liver fibrosis are at higher risk for (non-)fatal stroke, which is reduced with pravastatin.”

    Human trialhigh FIB-4 and obesity

    Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment

    European journal of clinical investigation

More on Stroke

Cardiovascular events

downin humans1RR 0.81

1 study
  1. Pravastatin lowers the risk of cardiovascular events in humans (Prediabetes with a history of myocardial infarction or unstable angina) (RR 0.81, 95% CI 0.70–0.95, p = 0.008).

    “pravastatin significantly reduced cardiovascular events in patients with prediabetes with a history of myocardial infarction or unstable angina”

    ReviewPrediabetes with a history of myocardial infarction or unstable angina

    Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials

    Medical sciences (Basel, Switzerland)

Amnesia

upin humans1

1 study
  1. Pravastatin is linked with a higher risk of amnesia in humans (ROR = 4.77, 95% CI: 3.76-6.06).

    “pravastatin (n = 68, ROR = 4.77, 95% CI: 3.76-6.06, P < 0.001)”

    Humansn = 68

    Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database

    Frontiers in pharmacology

More on Amnesia

Type 2 diabetes

upin humans1HR 1.19

1 study
  1. Pravastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.19, 95% CI 1.02-1.38).

    “pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

More on Type 2 diabetes

Cardiovascular disease

downin humans1RR 0.81

1 study
  1. Pravastatin lowers the risk of cardiovascular disease in humans (RR = 0.81, 95% CI = 0.72-0.91).

    “pravastatin significantly reduced the risks of total cardiovascular disease (RR = 0.81, 95% CI = 0.72-0.91)”

    Review

    Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants

    Nutrients

More on Cardiovascular disease

Coronary artery disease

downin humans1

1 study
  1. Pravastatin lowers the risk of coronary artery disease in humans (10-year projection from parametric survival models) (+77.9 days CHD-free survival, 95% CI 3.8-159.6, p=.046).

    “treated individuals would gain 77.9 days (95% CI=3.8-159.6, p=.046) of CHD-free survival”

    Human trial10-year projection from parametric survival models40 mg/d10 years projectedn = 2,867

    Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis

    Journal of the American Geriatrics Society

More on Coronary artery disease

Has pravastatin been tested in people?

6 of 95 about aging

Yes: 15 trials and 19 observational studies in people have been published, and 95 trials are registered.

Approved

Every condition in trials

40 of 74

Stopped

  • NCT04385433TerminatedBreast neoplasm

    Not enough patients enrolled

  • NCT03944512TerminatedPreeclampsia

    participants are no longer being examined or receiving intervention

  • NCT00467831TerminatedAlbinism

    insufficient enrollment

Who is developing pravastatin?

3 companies: Teva Pharmaceuticals USA, Mylan Pharmaceuticals and ViiV Healthcare.

Companies
  • Teva Pharmaceuticals USAPhase 1
  • Mylan PharmaceuticalsPhase 1therapeutic equivalency
  • ViiV HealthcarePhase 1HIV infection

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 5Feb 2026: 5Mar 2026: 3Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 3Sep 2026: 0Oct 2026: 1Nov 2026: 423 papers in 12 months

See all 90 papers on pravastatin